ESMO 2018 | Moving beyond monotherapy in HCC

Arndt Vogel

Some hepatocellular carcinoma (HCC) combination regimens including immunotherapy seem to be particularly promising, suggests Arndt Vogel, MD, PhD, of Hannover Medical School, Hannover, Germany, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Vogel also brings attention to the current lack of suitable biomarkers, which are needed to inform treatment strategies and/or identify mechanisms of resistance.

Share this video